President Joe Biden on Monday vetoed a once-bipartisan effort to add 66 federal district judgeships, saying “hurried action” by the House left important questions unanswered about the life-tenured positions. The legislation would have spread the establishment of the new trial court judgeships over more than a decade to give three presidential administrations and six Congresses the chance to appoint the new judges. The bipartisan effort was carefully designed, so lawmakers would not knowingly give an advantage to either political party in shaping the federal judiciary. The Democratic-controlled passed the measure unanimously in August. But the Republican-led House brought it to the floor only after Republican was re-elected to a second term in November. The White House had said at the time that would veto the bill. “The House of Representative’s hurried action fails to resolve key questions in the legislation, especially regarding how the new judgeships are allocated, and neither the House of Representatives nor the Senate explored fully how the work of senior status judges and magistrate judges affects the need for new judgeships,” the . “The efficient and effective administration of justice requires that these questions about need and allocation be further studied and answered before we create permanent judgeships for life-tenured judges,” Biden said. He said the bill would also have created new judgeships in states where senators have not filled existing judicial vacancies and those efforts “suggest that concerns about judicial economy and caseload are not the true motivating force behind passage of this bill now. “Therefore, I am vetoing this bill,” Biden said, essentially dooming the legislation for the current Congress. Overturning Biden’s veto would require a two-thirds majority in both the House and Senate, and the House vote fell well short of that margin. Organizations representing judges and attorneys had urged Congress to vote for the bill. They argued that the lack of new federal judgeships had contributed to profound delays in the resolution of cases and serious concerns about access to justice. Republican Sen. Todd Young of Indiana reacted swiftly, calling the veto a “misguided decision” and “another example of why Americans are counting down the days until President Biden leaves the White House.” He alluded to a that Biden recently granted his son Hunter on federal gun and tax charges. “The president is more enthusiastic about using his office to provide relief to his family members who received due process than he is about giving relief to the millions of regular Americans who are waiting years for their due process,” Young said. “Biden’s legacy will be ‘pardons for me, no justice for thee.’” The Western Journal has reviewed this Associated Press story and may have altered it prior to publication to ensure that it meets our editorial standards. We are committed to truth and accuracy in all of our journalism. Advertise with The Western Journal and reach millions of highly engaged readers, while supporting our work. .online games for couples 。

On Monday night, the entire Simpsons universe gets to experience it in a way not many could have imagined. The prime-time matchup between the Cincinnati Bengals and Dallas Cowboys will also take place at Springfield’s Atoms Stadium as part of “The Simpsons Funday Football” alternate broadcast. The altcast will be streamed on ESPN+, Disney+, and NFL+ (on mobile devices). ESPN and ABC have the main broadcast, while ESPN2 will carry the final “ManningCast” of the regular season. The replay will be available on Disney+ for 30 days. Globally, more than 145 countries will have access to either live or on replay. “We’re such huge football fans, and the Simpsons audience and the football audience, I feel, are like the same audience of just American families and football. And the Simpsons are so much a part of the DNA of the American family and culture that for us to, like, mush them together in this crazy video game, it’s so fun,” said Matt Selman, executive producer of “The Simpsons.” While the game is the focal point, the alternate broadcast, in some ways, will resemble a three-hour episode of “The Simpsons.” It starts with Homer eating too many hot dogs and having a dream while watching football. Homer joins the Cowboys in the dream while Bart teams up with the Bengals. Lisa and Marge will be sideline reporters. “That’s the beginning of the story, and the story continues through the entire game until Homer wakes up from his dream at the end of the game. It is like a complete story, and the NFL game will happen in between. It’s just going to be an amazing presentation with tons of surprises,” said Michael “Spike” Szykowny, ESPN’s VP of edit and animation. This is the second year ESPN has done an alternate broadcast for an NFL game. It used the characters from “Toy Story” for last year’s Sunday morning game from London between the Atlanta Falcons and Jacksonville Jaguars. “The Simpsons” has featured many sports-themed episodes during its 35 seasons. Even though “Homer at the Bat” remains the consensus favorite sports episode for many Simpsons fans, there have been football ones such as “Bart Star” and “Lisa The Greek.” There also was a Super Bowl-themed one after Fox’s broadcast of Super Bowl 33 between Denver and Atlanta in 1999. Even though “The Simpsons” remains a staple on Fox’s prime-time schedule, it is part of the Disney family after their acquisition of 20th Century Fox in 2019. All 35 seasons are on Disney+. The show’s creators have worked with ESPN and the NFL to make sure the look and sound is definitely Simpsonsesque. The theme song is a mash-up of “The Simpsons” opening and “Monday Night Football’s” iconic “Heavy Action.” There have also been pre-recorded skits and bits to use during the broadcast featuring Simpson’s legendary voices Hank Azaria, Nancy Cartwright, Dan Castellaneta, Julie Kavner, and Yeardley Smith. The telecast will be entirely animated, with the players’ movements in sync with what is happening in real-time on the field. That is done through player-tracking data enabled by the NFL’s Next Gen Stats system and Sony’s Beyond Sports Technology. While Next Gen Stats tracks where players are on the field with a tracking chip in the shoulder pads, there is skeletal data tracking and limb tracking data — which uses 29 points per player — to get closer to the player’s movements. The other data tracking will allow Beyond Sports and Disney to add special characters to the game. For example, there might be a play where Lisa catches the ball and goes 30 yards instead of Cincinnati’s Tee Higgins. “Lisa is much smaller than the rest of the players. So, in real life, the ball would go over her head, but now, with data processing, we can take the ball and make it go exactly into her hands. So for the viewer, it still looks believable, and it all makes sense,” said Beyond Sports co-founder Nicolaas Westerhof. The other major challenge is making “The Simpsons” two-dimensional cartoon characters into 3-D simulations. Szykowny and his team worked to make that a reality over the past couple of months. “That’s a big leap of faith for them to say, hey, we trust you to make our characters 3-D and work with it. Our ESPN creative studio team has done a wonderful job,” Szykowny said. Lisa, Krusty, Nelson, Milhouse and Ralph will be with Bart and the Bengals; while Carl, Barney, Lenny and Moe join up with with Homer and the Cowboys. The broadcast will also feature ESPN personalities Stephen A. Smith, Peyton Manning and Eli Manning. ESPN’s Drew Carter, Mina Kimes and Dan Orlovsky will call the game from Bristol, Connecticut, and also be animated. They will wear Meta Quest Pro headsets to experience the game from Springfield using VR technology. For Kimes, being part of the broadcast and being an animated Simpsons character is a dream come true. She is a massive fan of the show and has a framed photo of Lisa Simpson — who she said is a personal hero and icon — as part of her backdrop when she makes appearances on ESPN NFL shows from her home in Los Angeles. “I didn’t have any input, and I didn’t see anything beforehand, so I wasn’t sure if it would look like me, but it kind of does, which is very funny,” said Kimes, who drew Simpsons characters when she was a kid. “To see the actual staff turn me into one was a dream.” Even though the Bengals (4-8) and Cowboys (5-7) have struggled this season, Selman thinks both teams have personalities that appeal to “The Simpsons” universe. “We were just so lucky also that the Cowboys are sort of like a Homer Simpson-type team, American team, and Mike McCarthy might be a Homer-type guy, one might imagine,” he said. ”And then you have Joe Burrow on the other side who is a cool young, spiky-haired, blonde bad boy -- he’s like Bart. And that fits our character archetypes so perfectly. “If Homer is mad at Bart and has a hot dog dream while watching ’Monday Night Football’, and then it’s basically McCarthy versus Burrow, Homer versus Bart, and that’s the simple father versus son strangling — Homer strangling Bart dynamic that has been part of the show for 35 years. I don’t know if that would have worked as well if it was like Titans versus Jacksonville. We would have found something. We would have made it work.” AP NFL: https://apnews.com/hub/nflDisability ministers will ‘champion’ inclusion and accessibility, says TimmsDetails on Air Force's late-night visit to Reno, where it has played nothing but close games. Kickoff: 8:30 p.m., Mackay Stadium TV/Stream: FS1 – channel 11.1 in Colorado Springs on Comcast/Infinity (Channel 55/775 HD), DirecTV (Channel 219) and Dish (Channel 150). The game will also be streamed through Fox Sports website and app. Broadcast crew: Trent Rush (play-by-play), Petros Papadakis (analyst) Radio: KVOR AM 740 in Colorado Springs, 104.3 the Fan in Denver, SIRUS 387 Air Force broadcast crew: Jim Arthur (play-by-play), Jesse Kurtz (analyst) The Gazette’s Brent Briggeman identifies items of intrigue he’ll be tracking during the game. Can the defense do it again? The offense has been the primary driver of Air Force’s recent turnaround, picking up 47 first downs in the two games and running the clock. But the defense has obviously been a part of that. However, here’s another chance for the defense to show just how good it is. Against Fresno State, the Bulldogs offense was on the field for just 14:52 but averaged 7.5 yards per play. Part of that ability to quickly get off the field In a shutout came from stops, but part came from four scoring drives that averaged just 99 seconds apiece. In a shutout of Oregon State the Falcons were playing against a backup quarterback with only five career pass attempts prior to the game. Nevada, with an offense presumably intact, provides Air Force’s defense another opportunity to show how far is has come this season. Another close game? Air Force and Nevada have made a habit of playing close games, and that has especially been the case in games in Reno. The Falcons are 2-1 at Nevada, losing 45-42 in 2013, winning 45-42 in 2017 and prevailing 41-39 after three overtimes in 2021. The only game for Air Force this season that came down to the final possession was its 21-13 loss to Colorado State. History certainly suggests this could be another. The big picture(s) A two-game winning streak has placed Air Force in position where, if it can win its final two games, if just might land itself in a bowl game as a 5-7 replacement team should the slate not be filled. A loss would eliminate that hope. Also, sophomores have been emerging in recent weeks, with QB Quentin Hayes, OL Alec Falk, OLB David Santiago, ILB Blake Fletcher, DB Lincol Tuioti-Mariner and SS Houston Hendrix among the expected starters this week and fullback Owen Allen serving as the top backup at a prolific position on the offense. Can more sophomores (and juniors) continue to establish themselves, aiding the program as it nears the end of the season? Starting combinations for Air Force’s offensive line this season, only six teams have used more. However, the Falcons have started the same line for the past four games. Air Force’s national rank in rushing yards with 209.4 yards per game. The Falcons have finished in the Top 10 all but once since 1986. They ranked 36th just two weeks ago before running for a combined 614 yards in the past two games. Receptions for Air Force slot receiver Cade Harris, the most in a season for the Falcons since Geraud Sanders had 30 catches in 2019. Players on Nevada’s roster who transferred from teams in power conferences. Nevada’s third-down conversion percentage, the second best in the Mountain West and No. 14 nationally.

Lisa Simpson once said during an episode of “The Simpsons:” What could be more exciting than the savage ballet that is pro football? On Monday night, the entire Simpsons universe gets to experience it in a way not many could have imagined. The prime-time matchup between the Cincinnati Bengals and Dallas Cowboys will also take place at Springfield’s Atoms Stadium as part of “The Simpsons Funday Football” alternate broadcast. The altcast will be streamed on ESPN+, Disney+, and NFL+ (on mobile devices). ESPN and ABC have the main broadcast, while ESPN2 will carry the final “ManningCast” of the regular season. The replay will be available on Disney+ for 30 days. Globally, more than 145 countries will have access to either live or on replay. “We’re such huge football fans, and the Simpsons audience and the football audience, I feel, are like the same audience of just American families and football. And the Simpsons are so much a part of the DNA of the American family and culture that for us to, like, mush them together in this crazy video game, it’s so fun,” said Matt Selman, executive producer of “The Simpsons.” While the game is the focal point, the alternate broadcast, in some ways, will resemble a three-hour episode of “The Simpsons.” It starts with Homer eating too many hot dogs and having a dream while watching football. Homer joins the Cowboys in the dream while Bart teams up with the Bengals. Lisa and Marge will be sideline reporters. “That’s the beginning of the story, and the story continues through the entire game until Homer wakes up from his dream at the end of the game. It is like a complete story, and the NFL game will happen in between. It’s just going to be an amazing presentation with tons of surprises,” said Michael “Spike” Szykowny, ESPN’s VP of edit and animation. This is the second year ESPN has done an alternate broadcast for an NFL game. It used the characters from “Toy Story” for last year’s Sunday morning game from London between the Atlanta Falcons and Jacksonville Jaguars. “The Simpsons” has featured many sports-themed episodes during its 35 seasons. Even though “Homer at the Bat” remains the consensus favorite sports episode for many Simpsons fans, there have been football ones such as “Bart Star” and “Lisa The Greek.” There also was a Super Bowl-themed one after Fox’s broadcast of Super Bowl 33 between Denver and Atlanta in 1999. Even though “The Simpsons” remains a staple on Fox’s prime-time schedule, it is part of the Disney family after their acquisition of 20th Century Fox in 2019. All 35 seasons are on Disney+. The show’s creators have worked with ESPN and the NFL to make sure the look and sound is definitely Simpsonsesque. The theme song is a mash-up of “The Simpsons” opening and “Monday Night Football’s” iconic “Heavy Action.” There have also been pre-recorded skits and bits to use during the broadcast featuring Simpson’s legendary voices Hank Azaria, Nancy Cartwright, Dan Castellaneta, Julie Kavner, and Yeardley Smith. The telecast will be entirely animated, with the players’ movements in sync with what is happening in real-time on the field. That is done through player-tracking data enabled by the NFL’s Next Gen Stats system and Sony’s Beyond Sports Technology. While Next Gen Stats tracks where players are on the field with a tracking chip in the shoulder pads, there is skeletal data tracking and limb tracking data — which uses 29 points per player — to get closer to the player’s movements. The other data tracking will allow Beyond Sports and Disney to add special characters to the game. For example, there might be a play where Lisa catches the ball and goes 30 yards instead of Cincinnati’s Tee Higgins. “Lisa is much smaller than the rest of the players. So, in real life, the ball would go over her head, but now, with data processing, we can take the ball and make it go exactly into her hands. So for the viewer, it still looks believable, and it all makes sense,” said Beyond Sports co-founder Nicolaas Westerhof. The other major challenge is making “The Simpsons” two-dimensional cartoon characters into 3-D simulations. Szykowny and his team worked to make that a reality over the past couple of months. “That’s a big leap of faith for them to say, hey, we trust you to make our characters 3-D and work with it. Our ESPN creative studio team has done a wonderful job,” Szykowny said. Lisa, Krusty, Nelson, Milhouse and Ralph will be with Bart and the Bengals; while Carl, Barney, Lenny and Moe join up with with Homer and the Cowboys. The broadcast will also feature ESPN personalities Stephen A. Smith, Peyton Manning and Eli Manning. ESPN’s Drew Carter, Mina Kimes and Dan Orlovsky will call the game from Bristol, Connecticut, and also be animated. They will wear Meta Quest Pro headsets to experience the game from Springfield using VR technology. For Kimes, being part of the broadcast and being an animated Simpsons character is a dream come true. She is a massive fan of the show and has a framed photo of Lisa Simpson — who she said is a personal hero and icon — as part of her backdrop when she makes appearances on ESPN NFL shows from her home in Los Angeles. “I didn’t have any input, and I didn’t see anything beforehand, so I wasn’t sure if it would look like me, but it kind of does, which is very funny,” said Kimes, who drew Simpsons characters when she was a kid. “To see the actual staff turn me into one was a dream.” Even though the Bengals (4-8) and Cowboys (5-7) have struggled this season, Selman thinks both teams have personalities that appeal to “The Simpsons” universe. “We were just so lucky also that the Cowboys are sort of like a Homer Simpson-type team, American team, and Mike McCarthy might be a Homer-type guy, one might imagine,” he said. ”And then you have Joe Burrow on the other side who is a cool young, spiky-haired, blonde bad boy -- he’s like Bart. And that fits our character archetypes so perfectly. “If Homer is mad at Bart and has a hot dog dream while watching ’Monday Night Football’, and then it’s basically McCarthy versus Burrow, Homer versus Bart, and that’s the simple father versus son strangling — Homer strangling Bart dynamic that has been part of the show for 35 years. I don’t know if that would have worked as well if it was like Titans versus Jacksonville. We would have found something. We would have made it work.” AP NFL: https://apnews.com/hub/nfl

World's Leading Specialty Battery Franchise Achieves Historic Success with Unprecedented Commercial Sales Throughout 2024 Batteries Plus achieved a 23.7% year-over-year increase in total systemwide commercial sales for October 2024 . Franchise commercial sales grew by 24.4% in October, setting a new all-time monthly record. October's systemwide commercial sales marked nearly 20% growth year-over-year for Batteries Plus. HARTLAND, Wis. , Nov. 25, 2024 /PRNewswire/ -- Batteries Plus , the world's leading specialty battery franchise, has marked a historic milestone in October 2024 , setting all-time commercial sales records across its franchise and systemwide channels. Total systemwide commercial sales grew by 23.7% year-over-year, with franchise commercial sales increasing by 24.4%, marking the highest monthly performance in the company's history. The record-breaking success in October was not an isolated achievement, but rather a continuation of a historic 2024. Batteries Plus has experienced more than 20% year-over-year growth in systemwide commercial sales for five of the first 10 months of the year. Year-to-date, total commercial sales have grown by 16.1% through October. "Achieving this record-breaking October is a testament to the extraordinary efforts of our franchisees and the ongoing strength of our commercial growth strategy," said Scott O'Farrell , Chief Commercial Officer of Batteries Plus . "Our commitment to providing exceptional service and innovative solutions for our commercial partners continues to position us as a leader in the industry." This October milestone also capped off a flawless 10-for-10 streak in exceeding commercial sales targets for 2024, driven by Batteries Plus's commitment to exceptional service, in-stock availability, and a diversified approach across consumer and commercial channels. The company has exceeded its sales plan for every month, currently 2.6% ahead of plan through October. Remarkably, the top eight commercial sales months in franchise history have all occurred this year, demonstrating the strength and scalability of the franchise system. "October's success is just the beginning of an exciting period for Batteries Plus," said Joe Malmuth , Chief Development Officer . "We're witnessing substantial growth across all facets of the business. This record-breaking performance is a direct result of our team's tireless efforts to drive meaningful results for our franchise owners and customers alike." Building on this momentum, Batteries Plus is looking ahead to close the year strong, with plans to enhance its market presence, introduce new business partnerships, and continue the expansion of its franchise network that has reached over 800 store locations in operation and development nationwide. In 2024, Batteries Plus was ranked on Franchise Times' Top 400 list at #128 and named to Entrepreneur Magazine 's Franchise 500 ® Hall of Fame, alongside placements on Entrepreneur 's Franchise 500 ® and the Top Brands for Multi-Unit Owners lists. For more information on Batteries Plus, including franchise opportunities and a virtual store tour, visit batteriesplusfranchise.com . ABOUT BATTERIES PLUS: Batteries Plus, founded in 1988 and headquartered in Hartland, WI , is a leading omnichannel retailer of batteries, specialty light bulbs and phone repair services for the direct-to-consumer and commercial channels. The retailer also offers key programming, replacement and cutting services. Through a nationwide network of stores, the company offers a differentiated value proposition of unrivaled product selection, in-stock availability and customer service. Batteries Plus is owned by Freeman Spogli , a private equity firm based in Los Angeles and New York City . To learn more about one of Forbes ® ' Best Franchises to Buy in America, visit https://www.batteriesplusfranchise.com . MEDIA CONTACT: Danny Stewart , Fishman Public Relations, dstewart@fishmanpr.com or 847-945-1300 ext. 266 View original content to download multimedia: https://www.prnewswire.com/news-releases/batteries-plus-celebrates-record-breaking-commercial-sales-month-surpassing-major-milestones-in-franchise-and-systemwide-commercial-growth-302315675.html SOURCE Batteries Plus © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Buffalo Bills' week is already off to an interesting start thanks to latest injury updateMedicines for Cuba

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen

Smith scores 23 in Furman's 69-63 win against PrincetonNeuroscience Study Aboard Cunard's Queen Mary 2 Reveals Cognitive Benefits of Slow Travel at Sea

Feds suspend ACA marketplace access to companies accused of falsely promising ‘cash cards’

Special counsel moves to dismiss election interference and classified documents cases against Trump

Chad Chronister, Donald Trump’s pick to run the DEA, withdraws name from considerationThe game industry is no stranger to boom-and-bust cycles, in which scores of opportunistic developers fall over themselves to release copycat competitors to the latest massive hit, and most, if not all, fail. Perhaps the biggest instance — and certainly the most embarrassing for almost everyone concerned — was the race to release the mythical “ WoW killer” : a massively multiplayer online role-playing game that would unseat Blizzard’s global megahit, World of Warcraft , and earn its makers millions of dollars in monthly subscription revenue until the end of time. It turned out to be an industry-wide epic fail — and I had a ringside seat to this unfortunate spectacle. My career in games journalism began in 2004, just a few months before WoW was released. My obsessive love of the game threatened to tank that career before it had really begun, but instead I turned it to my advantage, specializing in covering a genre of game that was too arcane and time-consuming for most staff writers and editors to get their heads around. I traveled to scores of preview events for MMO hopefuls that public relations reps would optimistically tout as “ World of Warcraft , but for soccer,” or “ World of Warcraft , but for vehicular combat.” In 2008, I was hired by Eurogamer as the editor of its short-lived MMO section — let’s not pretend that we in the press were immune to the same wrongheaded gold-rush thinking — and discovered firsthand exactly why the whole enterprise was doomed to fail. One reason is that World of Warcraft — especially during its 2004-to-2010 heyday — was simply too good to beat. But another is that hit-chasing, not a great strategy at the best of times, is almost impossible to pull off in the world of social, online games. The hits garner intensely loyal, invested audiences who play them month in, month out, and who aren’t really looking for something else to move on to. Those audiences are hermetically sealed within their own fandoms and care much less about shiny graphics or other technical advancements, while the constantly updated games have plenty of room to innovate and evolve the genre within themselves. The time-honored tactic of “just slap a big license (like Star Wars) on it” is less effective in this sphere, too, because the appeal of famous characters and storylines doesn’t necessarily apply — the players are more invested in their communities. Yet the industry continues to make this critical error with online games. Just look at the spectacular crash and burn of Concord earlier this year, itself just the latest of countless attempts to elbow Overwatch off its hero-shooter throne. In the spirit of constructive learning, and only a little bit of schadenfreude , let’s look back at some of the games that failed to put a dent in World of Warcraft ’s hegemony... and the few that did. The failed WoW killers The Lord of the Rings Online (2007): This entry is perhaps a little unfair, since various people had been trying to make a Middle-earth MMO based on Tolkien’s works long before Blizzard had even thought of WoW . The original developer, an MMO specialist called Turbine, probably thought it was just making another niche online game before publisher WB Games got unduly excited about its potential. The game was fine, but clearly a generation behind WoW in terms of its design. People still play it, though! Age of Conan (2008): Oh dear . The first and most instructive case of post- WoW hubris came from Funcom, a Norwegian specialist that got way out of its depth trying to push cutting-edge graphics, gore, sex, and dynamic real-time swordfighting into an MMO based on Robert E. Howard’s lusty fantasy world. Publisher Eidos put all its chips down; I remember attending an absurd press event staged in Oslo’s 1952 Winter Olympic park, which had been transformed into a medieval setting with horse-riding barbarians and fireside feasting. (A PR rep I was with got very drunk and stole a sheepskin rug, roaring incoherently into the Scandinavian night while wearing it around his shoulders.) The game was a mess at launch, and tanked hard. Warhammer Online: Age of Reckoning (2008): EA’s big play made sense on paper; the Warhammer license is probably as close as you can legally get to the Warcraft setting, and developer Mythic’s Dark Age of Camelot was beloved by the MMO hardcore. The game was lavish and expensive but limited in design, too focused on massive player-versus-player combat whereas WoW excelled at embracing almost every possible play style. Warhammer Online was shut down in 2013. APB: All Points Bulletin (2010): A Grand Theft Auto-style massively multiplayer game boasting intense levels of player customization, and masterminded by GTA’s creator himself, David Jones? What could go wrong? Everything! APB was stacked with ambitious features but notably lacked, you know, gameplay. Also, Jones’ company Realtime Worlds, which had previously made the excellent Crackdown for Xbox, was in far too deep. A disastrous launch was followed within a couple of months by the developer going bankrupt and APB getting shut down. Another company bought and relaunched it, but didn’t succeed in putting an actual game in there. Rift (2011): The MMO gold rush wasn’t just about games; entire companies sprang up, drawing huge investment on the promise of some revolutionary technology or other. Trion Worlds was one example that boasted fancy server-side tech that was supposed to take MMOs closer to the fully simulated cloud-gaming dream. Unfortunately, its flagship fantasy MMO Rift was very boring. Star Wars: The Old Republic (2011): Smarting from the failure of Warhammer Online , EA was nevertheless up for another crack at smashing WoW , armed with the Star Wars license, its star in-house developer BioWare, and an apparently limitless budget. The hype was off the charts, but BioWare’s expertise was in single-player games. Everybody bought it, played the story through, and moved on, which is... not the idea. BioWare didn’t give up, though, and steadily built out a proper massively multiplayer game around the story campaigns. After a successful free-to-play relaunch, The Old Republic still has an audience. Guild Wars 2 (2012): Guild Wars 2 is actually a fantastic game, easily the best on this list — I feel bad including it. It has refined combat and employed several genre-defining ideas that were later copied by WoW , Destiny , and others. But the scope of this relatively streamlined game was not equal to the hopes publisher NCSoft loaded on it — and the ever-expanding WoW presented a moving target that could never be caught. WildStar (2014): NCSoft, a big player in Korea, made its most determined attempt to crack the West with WildStar , a game by former Blizzard devs with a very Warcraft-y color palette and art style. It was cute, expensive, action-forward, and had some fun ideas, but it was also very obviously a trend-chasing mishmash with no reason to exist beyond trying to top WoW . NCSoft shut it down and closed developer Carbine in 2018. The game almost did kill WoW Final Fantasy 14 (2013): The prize for perseverance goes to Square Enix, which simply didn’t give up — and which, importantly, had reasons other than competing with Blizzard to be making an MMO. Final Fantasy 11 had been a pre- WoW hit in 2002; the first attempt to follow it up with FF14 in 2010 was a disaster, but Square Enix bravely scrapped it and asked producer Naoki Yoshida for a complete do-over. It was a question of honor, if anything. Yoshida’s reboot ruled, and Square Enix didn’t falter when it didn’t immediately do WoW numbers, but continued to invest. FF14 steadily got bigger and better, and it was ready and waiting when Blizzard stumbled through a succession of PR disasters and lackluster WoW expansions in the late 2010s and early 2020s. WoW streamers and players starting leaving for FF14 in droves, and Square Enix’s game is, at last, the competitor that WoW has always deserved. Analysis Fantasy Gaming PC World of Warcraft World of Warcraft

MUNICH (AP) — Harry Kane is the quickest player to score 50 goals in the Bundesliga after scoring a hat trick on his 43rd appearance on Friday. Kane’s three goals – including two penalties – gave Bayern a 3-0 win over Augsburg , stretching the Bavarian powerhouse’s lead to eight points ahead of the rest of the 11th round. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Omaha (US), Nov 25 (AP) Investor Warren Buffett renewed his Thanksgiving tradition of giving by announcing plans Monday to hand more than USD 1.1 billion of Berkshire Hathaway stock to four of his family's foundations, and he offered new details about who will be handing out the rest of his fortune after his death. Buffett has said previously that his three kids will distribute his remaining USD 147.4 billion fortune in the 10 years after his death, but now he has also designated successors for them because it's possible that Buffett's children could die before giving it all away. He didn't identify the successors, but said his kids all know them and agree they would be good choices. “Father time always wins. But he can be fickle – indeed unfair and even cruel – sometimes ending life at birth or soon thereafter while, at other times, waiting a century or so before paying a visit,” the 94-year-old Buffett said in a letter to his fellow shareholders. “To date, I've been very lucky, but, before long, he will get around to me. There is, however, a downside to my good fortune in avoiding his notice. The expected life span of my children has materially diminished since the 2006 pledge. They are now 71, 69 and 66.” Buffett said he still has no interest in creating dynastic wealth in his family — a view shared by his first and current wives. He acknowledged giving Howard, Peter and Susie millions over the years, but he has long said he believes “hugely wealthy parents should leave their children enough so they can do anything but not enough that they can do nothing”. The secret to building up such massive wealth over time has been the power of compounding interest and the steady growth of the Berkshire conglomerate Buffett leads through acquisitions and smart investments like buying billions of dollars of Apple shares as iPhone sales continued to drive growth in that company. Buffett never sold any of his Berkshire stock over the years and also resisted the trappings of wealth and never indulged in much — preferring instead to continue living in the same Omaha home he'd bought decades earlier and drive sensible luxury sedans about 20 blocks to work each day. “As a family, we have had everything we needed or simply liked, but we have not sought enjoyment from the fact that others craved what we had,” he said. If Buffett and his first wife had never given away any of their Berkshire shares, the family's fortune would be worth nearly USD 364 billion — easily making him the world's richest man — but Buffett said he had no regrets about his giving over the years. The family's giving began in earnest with the distribution of Susan Buffett's USD 3 billion estate after her death in 2004, but really took off when Warren Buffett announced plans in 2006 to make annual gifts to the foundations run by his kids along with the one he and his wife started, as well as the Bill and Melinda Gates Foundation. Warren Buffett's giving to date has favoured the Gates Foundation with USD 55 billion in stock because his friend Bill Gates already had his foundation set up and could handle huge gifts when Buffett started giving away his fortune. But Buffett has said his kids now have enough experience in philanthropy to handle the task and he plans to cut off his Gates Foundation donations after his death. Buffett always makes his main annual gifts to all five foundations every summer, but for several years now he has been giving additional Berkshire shares to his family's foundations at Thanksgiving. Buffett reiterated Monday his advice to every parent to allow their families to read their will while they are still alive — like he has done — to make sure they have a chance to explain their decisions about how to distribute their belongings and answer their children's questions. Buffett said he and his longtime investing partner Charlie Munger, who died a year ago, “saw many families driven apart after the posthumous dictates of the will left beneficiaries confused and sometimes angry”. Today, Buffett continues to lead Berkshire Hathaway as chairman and CEO and has no plans to retire although he has handed over most of the day-to-day managing duties for the conglomerates dozens of companies to others. That allows him to focus on his favourite activity of deciding where to invest Berkshire's billions. One of Buffett's deputies who oversees all the noninsurance companies now, Greg Abel, is set to take over as CEO after Buffett's death. (AP) PY PY (This story has not been edited by THE WEEK and is auto-generated from PTI)

2024 in pop culture: In a bruising year, we sought out fantasy, escapism — and cute little animalsNoneSebastian Zapeta, 33, who federal immigration officials said is a Guatemalan citizen who entered the US illegally, was arraigned in Brooklyn criminal court. He appeared briefly before a judge and wore a white jumpsuit over a weathered black hooded sweatshirt. He did not speak. He will remain jailed ahead of his next court date on Friday. The apparently random attack occurred on Sunday morning on a stationary F train at the Coney Island station in Brooklyn. Police said on Tuesday that identification of the victim was still “pending at this time”. Authorities say Zapeta approached the woman, who was sitting motionless in the train car and may have been sleeping, and used a lighter to set her clothing on fire. The woman quickly became engulfed in flames, while the suspect then sat at a bench on the subway platform and watched, according to police. Video posted to social media appeared to show the woman standing inside the train ablaze as some people look on from the platform, and at least one officer walks by. NYPD chief of transit Joseph Gulotta said that several officers had responded to the fire and one stayed to keep the crime scene “the way it’s supposed to be” while the others went to get fire extinguishers and transit workers. They were eventually able to douse the fire, but “unfortunately, it was too late”, Police Commissioner Jessica Tisch said — the woman was pronounced dead at the scene. During Zapeta’s court hearing on Tuesday, Assistant District Attorney Ari Rottenberg said Zapeta at one point fanned the flames on the woman using his shirt. He said a 911 call from a subway rider helped identify Zapeta. Mr Rottenberg added that under interrogation Zapeta claimed he did not know what happened, noting that he consumes alcohol. But he alleged that Zapeta identified himself to interrogators in images related to the attack. Zapeta was taken into custody on Sunday afternoon while riding a train on the same subway line after police got a tip from some teenagers who recognised him from images circulated by the police. A Brooklyn address for Zapeta released by police matches a shelter that provides housing and substance abuse support. The shelter did not immediately respond to a request for comment. Federal immigration officials said Zapeta had been previously deported in 2018 but at some point reentered the US illegally. The crime — and the graphic video of it that ricocheted across social media — deepened a growing sense of unease among some New Yorkers about the safety of the subway system in a city where many residents take the subway multiple times each day.IF Christmas shopping seems like a chore, why not pop into one of Primark’s Disney cafes for a festive pick-me-up? The budget retailer has revealed its Christmas menu which has launched, and it looks mouthwatering. After browsing for Christmas gifts or party outfits, why not sit down for one of their waffles or cheesy festive toasties. There is also a “selection of merry milkshakes and hot and cold drinks for everyone to enjoy.” A clip was posted on the Immersive Cafe’s Instagram page, after they decked out the Primark food spot for December. They wrote: “POV: the Primark Disney Café Menu has dropped! “The Primark Disney Christmas Cafés menu has dropped at both Merry Hill and Belfast and they’ve not held back on the magic! “From heartwarming waffles to cheesy festive toasties, a selection of merry milkshakes and hot and cold drinks for everyone to enjoy. “You don’t want to miss out on this festive treat!” If you can’t make it to the Merry Hill or Belfast stores, panic not. Primark also has six cafe locations across the UK that are themed on The Grinch. The retailer has partnered with Dr Seuss to create a Grinch’s green lair with a limited-edition menu. Primark’s Grinch Cafes are sure to be a hit with fans of the furry character, with everything from green waffles and shakes to get in the anti-Christmas spirit. There are also festive toasties and hot drinks to warm even the frostiest of hearts . Customers can tuck into a variety of dishes including ‘Holiday Cheer’ waffles with ice cream, chocolate sauce, chocolate orange pieces and popping candy, tasty turkey , brie and cranberry toasties and special drinks like the ‘Strawberry Cindy-Lou Who’ milkshake and a mince pie iced latte. The Grinch cafe is open in Primark’s stores in Birmingham , Manchester Trafford, Manchester Market Street, Cardiff , Braehead and Edinburgh until the end of December. The furry green icon - played by Jim Carrey in the 2000 hit movie - has become a staple beloved character over the years, for both kids and adults alike. After tucking into themed drinks and food, shoppers can then check out Primark’s new Grinch-inspired range. From themed matching pjs for the whole family, to comfy slippers and even Grinch stockings, you can turn your home into a Who-ville haven this year. Shoppers are already going into a frenzy to pick up items from the collection based on the Christmas-hating Dr Seuss character. PRIMARK first opened in 1969 as Pennies in Dublin, hoping to provide affordable fashion in Ireland. A Primark store officially opened as Primark in 1974 in Derby. The retailer now has 193 stores across the UK and 441 stores worldwide with a goal of running 530 stores by the end of 2026.